|"VIVE set new records in Q4/16 in console and treatment tip sales."|
|"The validation program for DXD's Hodgkin's lymphoma test (Telo-HL) is under way."|
|"RP announced that it has identified two new two European manufacturers with which it will collaborate going forward on development of its patented Pelletier element cooled dermal injector RCI-02."|
– Ed Arce, H.C. Wainwright & Co.
|"INO's preliminary data show immune responses in 100% of Zika-vaccinated and 98% of MERS-vaccinated human subjects."|
|"DRRX provided a 4Q16 earnings update and indicated that they are actively working towards commencing a Phase 2 trial with an oral formulation of DUR-928 for PSC."|
|"End of phase II meetings with both the FDA and EMA have given INO a path forward for a pivotal study of VGX-3100."|
|"RP has successfully completed its first-in-human clinical study of the company's autologous cell therapy for the treatment of androgenetic alopecia."|